Incyte Genomics Inc (INCY) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with N...
Incyte Genomics Inc (INCY) currently trades at a P/E ratio of 14.21 (historical range: 13.32–663.64, median: 19.76), placing it at the 4th percentile — cheap relative to its history, P/S ratio of 3.94 (range: 2.48–6.24, 42th percentile — near its historical average), EV/EBITDA of 10.36 (range: 9.72–12.60, 16th percentile).
Over the historical period (2021-09-14 to 2026-10-16), Incyte Genomics Inc's P/E ratio has expanded by 663% over the observed period (from an average of 26.7 to 203.9).
Incyte Genomics Inc trades well below its historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 14.21 | 19.76 | 4th | cheap relative to its history |
| P/S Ratio | 3.94 | 4.04 | 42th | near its historical average |
| EV/EBITDA | 10.36 | 10.97 | 16th | cheap relative to its history |
| FCF Yield | 8.36% | 4.04% | 98th | cheap relative to its history |
Incyte Genomics Inc (INCY) Valuation & P/E History
Incyte Genomics Inc (INCY) is a US-listed stock operating in the Healthcare sector, specifically the Services-Commercial Physical & Biological Research industry currently trading at $113.07 with a market capitalization of $22.9 billion. This page provides historical valuation analysis for INCY based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 14.21 is below the historical median of 19.76, placing INCY at the 4th percentile of its valuation range. The P/S ratio of 3.94 compares to a median of 4.04.
INCY Valuation Metrics & Historical Range
The valuation table above shows Incyte Genomics Inc's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether INCY is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests INCY is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Incyte Genomics Inc.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is INCY Overvalued or Undervalued?
Incyte Genomics Inc trades well below its historical valuation range across most metrics. The overall valuation percentile of 21 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive INCY is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full INCY analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.INCY trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.